December 4, 2019 11:32 AM EST

FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs

Kathy Wong

Editor

→ Celgene and Acceleron‘s Reblozyl (luspatercept) earned an OK from the FDA last month to treat anemia in adults who require regular transfusions, but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA will con­vene ad­comm for Bris­tol-My­er­s' Re­blozyl in MDS; FDA grants 'or­phan' tags to a trio of drugs

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs